Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DESIPRAMINE

3 general benefit · 4 not a benefit

Other products in the same Health Canada class (N06AA) — coverage varies; not interchangeable

  • Amitriptyline (Elavil): general benefit
  • Clomipramine (Anafranil Tab): general benefit
  • Doxepin (Sinequan): general benefit, Not a benefit
  • Imipramine (Tofranil): general benefit, Not a benefit
  • Nortriptyline (Aventyl): general benefit
  • Trimipramine (Surmontil): general benefit, Not a benefit

17 more in the class list below

Desipramine · DIN 02216256 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Desipramine · DIN 02216256 Manufacturer: A A Pharma Inc.; listing date 1996-12-19 Health Canada: Marketed since 2022-12-16 · brand DESIPRAMINE · ATC N06AA01 DESIPRAMINE · form Tablet · route Oral · ingredients DESIPRAMINE HYDROCHLORIDE 25 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Desipramine: Formulary list price $0.4441/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4441 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20015 · Verify on the e-Formulary ↗ (DIN 02216256)

Source record
DIN 02216256: Desipramine Raw flags: sec3=Y Item: 281604007; group id 456; item number 1138; lccId None; manufacturer id AAP Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.4441; ministry $0.4441 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02216256 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20015
Interchangeable products
Norpramin · DIN 02099128 · not recorded Pertofrane · DIN 00010448 · not recorded
Shortage status: resolved shortage (ended 2024-04-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02216256
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Desipramine · DIN 02216264 · 50mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Desipramine · DIN 02216264 Manufacturer: A A Pharma Inc.; listing date 1996-12-19 Health Canada: Marketed since 2022-12-16 · brand DESIPRAMINE · ATC N06AA01 DESIPRAMINE · form Tablet · route Oral · ingredients DESIPRAMINE HYDROCHLORIDE 50 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Desipramine: Formulary list price $0.7827/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7827 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20023 · Verify on the e-Formulary ↗ (DIN 02216264)

Source record
DIN 02216264: Desipramine Raw flags: sec3=Y Item: 281604006; group id 456; item number 1139; lccId None; manufacturer id AAP Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.7827; ministry $0.7827 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02216264 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20023
Interchangeable products
Norpramin · DIN 02099136 · not recorded
Shortage status: resolved shortage (ended 2024-10-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02216264
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Desipramine · DIN 02216272 · 75mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Desipramine · DIN 02216272 Manufacturer: A A Pharma Inc.; listing date 1996-12-19 Health Canada: Marketed since 2022-12-16 · brand DESIPRAMINE · ATC N06AA01 DESIPRAMINE · form Tablet · route Oral · ingredients DESIPRAMINE HYDROCHLORIDE 75 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Desipramine: Formulary list price $1.0408/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.0408 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20022 · Verify on the e-Formulary ↗ (DIN 02216272)

Source record
DIN 02216272: Desipramine Raw flags: sec3=Y Item: 281604034; group id 456; item number 1140; lccId None; manufacturer id AAP Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $1.0408; ministry $1.0408 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02216272 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20022
Interchangeable products
Norpramin · DIN 02099144 · not recorded
Shortage status: resolved shortage (ended 2018-12-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02216272
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Norpramin · DIN 02099128 · 25mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-08-01 — choose a marketed DIN from the same-category list.Discontinued 2007-08-01 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-08-01 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2007-08-01 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Norpramin · DIN 02099128 Manufacturer: Sanofi Aventis Pharma; listing date 1999-01-07 Health Canada: Cancelled post market since 2007-08-01 · brand NORPRAMIN 25MG TAB · ATC N06AA01 DESIPRAMINE · form Tablet · route Oral · ingredients DESIPRAMINE HYDROCHLORIDE 25 MG · company Sanofi-aventis canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Norpramin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18678 · Verify on the e-Formulary ↗ (DIN 02099128)

Source record
DIN 02099128: Norpramin Raw flags: notABenefit=Y, sec3=Y Item: 281604007; group id 456; item number 1138; lccId None; manufacturer id SAV Source form: Tab; strength: 25mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02099128 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18678
Interchangeable products
Desipramine · DIN 02216256 · $0.4441 Pertofrane · DIN 00010448 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02099128
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2007-08-01 — choose a marketed DIN from the same-category list.

Pertofrane · DIN 00010448 · 25mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1999-08-04 — choose a marketed DIN from the same-category list.Discontinued 1999-08-04 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1999-08-04 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 1999-08-04 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Pertofrane · DIN 00010448 Manufacturer: Geigy Pharmaceuticals,Division of Ciba-Geigy Canada Ltd.; listing date 1996-10-01 Health Canada: Cancelled post market since 1999-08-04 · brand PERTOFRANE 25MG · ATC N06AA01 DESIPRAMINE · form Tablet · route Oral · ingredients DESIPRAMINE HYDROCHLORIDE 25 MG/TAB · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Pertofrane: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1098 · Verify on the e-Formulary ↗ (DIN 00010448)

Source record
DIN 00010448: Pertofrane Raw flags: notABenefit=Y, sec3=Y Item: 281604007; group id 456; item number 1138; lccId None; manufacturer id GEI Source form: Tab; strength: 25mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00010448 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1098
Interchangeable products
Desipramine · DIN 02216256 · $0.4441 Norpramin · DIN 02099128 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00010448
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 1999-08-04 — choose a marketed DIN from the same-category list.

Norpramin · DIN 02099136 · 50mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-08-01 — choose a marketed DIN from the same-category list.Discontinued 2007-08-01 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-08-01 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2007-08-01 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Norpramin · DIN 02099136 Manufacturer: Sanofi Aventis Pharma; listing date 1999-01-07 Health Canada: Cancelled post market since 2007-08-01 · brand NORPRAMIN 50MG TAB · ATC N06AA01 DESIPRAMINE · form Tablet · route Oral · ingredients DESIPRAMINE HYDROCHLORIDE 50 MG · company Sanofi-aventis canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Norpramin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18677 · Verify on the e-Formulary ↗ (DIN 02099136)

Source record
DIN 02099136: Norpramin Raw flags: notABenefit=Y, sec3=Y Item: 281604006; group id 456; item number 1139; lccId None; manufacturer id SAV Source form: Tab; strength: 50mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02099136 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18677
Interchangeable products
Desipramine · DIN 02216264 · $0.7827
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02099136
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2007-08-01 — choose a marketed DIN from the same-category list.

Norpramin · DIN 02099144 · 75mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-08-16 — choose a marketed DIN from the same-category list.Discontinued 2000-08-16 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-08-16 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2000-08-16 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Norpramin · DIN 02099144 Manufacturer: Hoechst Marion Roussel Canada Inc.; listing date 1999-01-07 Health Canada: Cancelled post market since 2000-08-16 · brand NORPRAMIN 75MG TAB · ATC N06AA01 DESIPRAMINE · form Tablet · route Oral · ingredients DESIPRAMINE HYDROCHLORIDE 75 MG/TAB · company Aventis pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Norpramin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19892 · Verify on the e-Formulary ↗ (DIN 02099144)

Source record
DIN 02099144: Norpramin Raw flags: notABenefit=Y, sec3=Y Item: 281604034; group id 456; item number 1140; lccId None; manufacturer id HMR Source form: Tab; strength: 75mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02099144 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19892
Interchangeable products
Desipramine · DIN 02216272 · $1.0408
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02099144
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2000-08-16 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered

Matched class: 28:16:04 Antidepressants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMITRIPTYLINE, CLOMIPRAMINE HCL, FLUVOXAMINE MALEATE, NORTRIPTYLINE, PHENELZINE SULFATE, SERTRALINE HCL, TRANYLCYPROMINE SULFATE, VENLAFAXINE HCL, VORTIOXETINE HYDROBROMIDE Some products covered without a code (check the product listing): CITALOPRAM HYDROBROMIDE, DOXEPIN HCL, DULOXETINE, ESCITALOPRAM, FLUOXETINE HCL, IMIPRAMINE, MIRTAZAPINE, MOCLOBEMIDE, PAROXETINE HCL, TRAZODONE HYDROCHLORIDE, TRIMIPRAMINE 28:16:04 Antidepressants

AMITRIPTYLINE

· 12 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CLOMIPRAMINE HCL

· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab

DOXEPIN HCL

· 20 products · General benefit (12), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Cap

IMIPRAMINE

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 10mg, 25mg, 50mg · Tab

NORTRIPTYLINE

· 2 products · General benefit · strengths: 10mg, 25mg · Cap

TRIMIPRAMINE

· 10 products · Listed, not a benefit (5), General benefit (5) · strengths: 75mg, 12.5mg, 25mg, 50mg, 100mg · Cap, Tab

CITALOPRAM HYDROBROMIDE

· 51 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) · strengths: 10mg, 20mg, 40mg · Tab

DULOXETINE

· 38 products · Listed, not a benefit (2), General benefit (36) · strengths: 30mg, 60mg · DR Cap

ESCITALOPRAM

· 40 products · Listed, not a benefit (2), General benefit (38) · strengths: 10mg, 20mg · Orally Disintegrating Tab, Orally Disintegrating Tablet, Tab

FLUOXETINE HCL

· 41 products · Off-Formulary Interchangeable, not an ODB benefit (17), Listed, not a benefit (2), General benefit (22) · strengths: 10mg, 20mg, 40mg, 60mg, 20mg/5mL · Cap, Oral Sol

FLUVOXAMINE MALEATE

· 6 products · General benefit · strengths: 50mg, 100mg · Tab

MIRTAZAPINE

· 25 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 15mg, 30mg, 45mg · Orally Disintegrating Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:04 and 12 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS DESIPRAMINE (desipramine hydrochloride) is indicated for: • the treatment of endogenous depressive illness, including the depressed phase of manic depressive illness, involutional melancholia and psychotic depression. It may also be indicated in the management of depression of a non-psychotic degree such as in selected cases of depressive neurosis. Patients with transient mood disturbances or normal grief reaction are not expected to benefit from tricyclic antidepressants. 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. See 7 WARNINGS AND PRECAUTIONS, Psychiatric, Potential Association with Behavioural and Emotional Changes, including Self-Harm. 1.2 Geriatrics Geriatrics: Use in the geriatric population is associated with differences in safety See 7.1.4 Geriatrics. https://pdf.hres.ca/dpd_pm/00068795.PDF PM date: DEC 14, 2022 Source product: DESIPRAMINE; DIN 02216256; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Norpramin, Pertofrane: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026